Apeiron Investment Group is a family office and asset management firm that focuses on investments in biotechnology, deep tech, life sciences, and real estate companies. It completes deals across the entire lifecycle and balance sheet of a company, from non-listed seed/start-up investments to larger-scale restructuring and special situations deals. Apeiron's current portfolio encompasses more than 80 high-growth tech companies in Europe, the United States, and Asia.
When Apeiron sees major trends and structural changes happening in one of its core sectors, it regularly sets up and invests in platform companies in order to make concentrated and focused bets and acquisitions.
Apeiron takes active minority stakes in listed companies mainly through IPOs & SPACs, but sometimes also later in a company’s life cycle.
Apeiron has been a major driver of the long-deserved ‘psychedelic renaissance’ as a potential treatment for various mental health issues.